Allena Pharmaceuticals, Inc.

87 articles with Allena Pharmaceuticals, Inc.

• Allena Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update

  12/14/2017

  As of September 30, 2017, cash and cash equivalents were $33.9 million, as compared to cash, cash equivalents and short-term investments of $48.8 million as of December 31, 2016.

• 

  4 Solid Biotechs to Load Up on This Month

  12/4/2017

  Barring a huge meltdown, the S&P 500 will once again have a double-digit year of gains, and most investors should be looking at their 401(k)s and other accounts with some added holiday cheer.

• Allena Pharma Announces Pricing of Initial Public Offering

  11/2/2017

  The company announced the pricing of its initial public offering of 5,333,333 shares of common stock at a public offering price of $14.00 per share.

• Allena Pharma Eyes $92 Million Despite Failed Mid-Stage Trial

  10/9/2017

• European Commission (EC) Grants Orphan Drug Designation To Allena Pharma’ Investigational Therapy For The Treatment Of Primary Hyperoxaluria

  7/27/2017

• FDA Grants Orphan Drug Designation To Allena Pharma’ Investigational Therapy For The Treatment Of Primary Hyperoxaluria

  7/13/2017

• Allena Pharma And Health Advances, LLC Present Analysis Of Recurrent Kidney Stone Disease At The Academy Of Managed Care Pharmacy Nexus Conference

  10/4/2016

• Allena Pharma Taps AstraZeneca PLC Exec as New CFO

  9/7/2016

• Allena Pharmaceuticals, Inc. To Present At The 2016 Jefferies Healthcare Conference

  6/2/2016

• FDA Grants Orphan Drug Designation To Allena Pharmaceuticals, Inc.’s Investigational Therapy For The Treatment Of Pediatric Hyperoxaluria

  5/5/2016

• Allena Pharmaceuticals, Inc. To Present At The 36th Annual Cowen and Company Health Care Conference

  3/1/2016

• Allena Pharmaceuticals, Inc. Initiates Patient Treatment In Third Phase 2 Trial Of ALLN-177 For Secondary Hyperoxaluria

  2/10/2016

• Allena Pharmaceuticals, Inc. To Present At The 34th Annual J.P. Morgan Healthcare Conference

  1/11/2016

• Allena Pharmaceuticals, Inc. Announces Presentation Of Successful Phase 2 Data From ALLN-177 Program At American Society of Nephrology Kidney Week

  11/12/2015

• Allena Pharmaceuticals, Inc. Announces Presentation Of Successful Phase 2 Data From ALLN-177 Program At American Society of Nephrology Kidney Week

  11/12/2015

• Allena Pharmaceuticals, Inc. To Present Phase 2 Data On ALLN-177 Program At American Society of Nephrology Kidney Week 2015

  11/4/2015

• Allena Pharmaceuticals, Inc. To Present Phase 2 Data On ALLN-177 Program At American Society of Nephrology Kidney Week 2015

  11/4/2015

• Allena Pharmaceuticals, Inc. Initiates Phase IIb Trial Of ALLN-177 For Secondary Hyperoxaluria

  8/4/2015

• Allena Pharmaceuticals, Inc. Appoints Louis Brenner, M.D. As Chief Operating Officer

  4/16/2015

• Allena Pharmaceuticals, Inc. Announces Positive Phase IIa Data Of ALLN-177 For The Treatment Of Hyperoxaluria

  3/18/2015